Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Carcinoma, Renal Cell 6Brenner Tumor 6Melanoma 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colonic Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

cobimetinib 1atezolizumab 1Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Mucinous × Disulfides × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡